Systems and methods for visualizing ablated tissue

US9014789B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9014789-B2
Application numberUS-201213624899-A
CountryUS
Kind codeB2
Filing dateSep 22, 2012
Priority dateSep 22, 2011
Publication dateApr 21, 2015
Grant dateApr 21, 2015

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Systems and methods for visualizing ablated tissue are disclosed. In some embodiments, a system for imaging tissue includes a catheter having an expandable balloon at a distal end, an illumination device positioned within the balloon for propagating light from an external light source for illuminating a tissue being treated to excite native nicotinamide adenine dinucleotide hydrogen (NADH) in the tissue, and an imaging device positioned within the balloon for detecting fluorescence from the illuminated tissue, the imaging device being configured to communicate detected NADH fluorescence to an external fluorescence camera.

First claim

Opening claim text (preview).

What is claimed is: 1. A catheter to image ablated endocardial heart muscle tissue comprising: a balloon positioned about a distal end of the catheter, the balloon being inflatable with a transparent fluid for displacing surrounding blood to allow visualization of NADH fluorescence; an ultra-violet illumination device disposed at the distal end of the catheter for exciting mitochondrial NADH of the pulmonary vein and left atrial tissue; a fiberscope disposed at the distal end of the catheter for detecting NADH fluorescence from the illuminated pulmonary vein and left atrial tissue at the distal end; and a fluorescence camera at the proximal end of the catheter for creating a fluorescence image from the detected NADH fluorescence captured by the fiberscope, wherein the detected fluorescence image shows the physiology of the ablated lesion having a dark appearance due to lack of fluorescence, gaps having a light appearance due to normal fluorescence, and any ischemic tissue having a brighter halo type appearance surrounding the ablated lesion, and wherein the fluorescence camera includes a 460 nm band-pass filter to detect the NADH fluorescence from the illuminated pulmonary vein and left atrial tissue. 2. The catheter of claim 1 , wherein the fluorescence camera is a CCD camera. 3. The catheter of claim 1 , wherein the fiberscope is an optical imaging bundle. 4. A method for imaging a treated tissue comprising: ablating a heart tissue; illuminating, using an ultraviolet light source, the ablated tissue and untreated tissue around the ablated tissue to excite NADH in the tissue; imaging fluorescence of NADH in the illuminated tissue to produce a display of the imaged, illuminated tissue, the display illustrating the ablated tissue as having less fluorescence than the untreated tissue around the ablated tissue; distinguishing between the ablated tissue and ischemic tissue based on the amount of fluorescence; and ablating additional ischemic tissue identified by distinguishing between ablated tissue and ischemic tissue based on the amount of fluorescence. 5. The method of claim 4 , wherein the step of illuminating comprises exciting mitochondrial NADH. 6. The method of claim 4 , wherein distinguishing between the ablated tissue and ischemic tissue is based on a dark appearance due to lack of fluorescence of the ablated tissue and a lighter appearance of the ischemic tissue. 7. The method of claim 4 further comprising capturing light emitted from the illuminated tissue. 8. The method of claim 4 further comprising imaging treated tissue in real time. 9. The method of claim 4 further comprising using the imaging of treated tissue forms as the basis for a repeat or therapeutic procedure or follow-up revision procedure.

Assignees

Inventors

Classifications

  • A61B5/0071Primary

    by measuring fluorescence emission · CPC title

  • at distal tip of an endoscope · CPC title

  • with light-conductive means, e.g. fibre optics (A61B1/07 takes precedence) · CPC title

  • for introduction into the body, e.g. by catheters (A61B5/1459 takes precedence) · CPC title

  • combined with or comprising means for visual or photographic inspections inside the body, e.g. endoscopes · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9014789B2 cover?
Systems and methods for visualizing ablated tissue are disclosed. In some embodiments, a system for imaging tissue includes a catheter having an expandable balloon at a distal end, an illumination device positioned within the balloon for propagating light from an external light source for illuminating a tissue being treated to excite native nicotinamide adenine dinucleotide hydrogen (NADH) in t…
Who is the assignee on this patent?
Univ George Washington
What technology area does this patent fall under?
Primary CPC classification A61B5/0071. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).